secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-273228
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema Q3 net loss $42.2M; cash $329M; initiates OPERA-02 Phase 3; Pfizer deal
-----------------------------------------------------------------------------

- Net loss $42.2M for Q3 2025 vs $34.6M Q3 2024; cash, equivalents and securities $329.0M.
- Initiated OPERA-02 Phase 3 trial of palazestrant + ribociclib in frontline ER+/HER2- MBC.
- Clinical trial agreement with Pfizer to evaluate palazestrant + atirmociclib in Phase 1b/2.
- Phase 1/2 of OP-3136 (KAT6 inhibitor) expanded into combos; initial results expected mid-2026.
- Top-line data from OPERA-01 monotherapy Phase 3 expected in second half of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000119312525273228/0001193125-25-273228-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000119312525273228/olma-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-273228

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer